Patient story · Shenzhen
F. (52, United Arab Emirates) — Mesenchymal stem cell therapy for knee osteoarthritis
Dubai businessman avoided knee replacement with autologous mesenchymal stem cell injections — pain score down 70% at 6 months.
F. (52, Dubai) had grade 3 medial-compartment knee osteoarthritis but wanted to delay replacement. Stem cell therapy is regulated out of routine clinical practice in most home jurisdictions; HKU-Shenzhen runs a recognised regenerative medicine programme under approved trial protocols.
After workup, he received two rounds of autologous bone-marrow-derived MSC injections eight weeks apart. Total cost: $8,200 USD all-in including hotel. At 6-month follow-up: WOMAC pain score down 72%, function up 58%; he resumed competitive padel at month 5 with hyaluronic-acid bridging.
Outcome remains under longitudinal follow-up; F. returns annually for repeat assessment.
Have a similar case?
We'll return two competing Class A hospital quotes — broken out line-by-line — within 5 business days. No obligation.